Drug-induced hyperuricaemia and gout.
Ben Salem C, Slim R, Fathallah N, Hmouda H.
Rheumatology (Oxford). 2017 May 1;56(5):679-688. doi: 10.1093/rheumatology/kew293.
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease.
Costa TEM, Lauar JC, Innecchi MLR, Coelho VA, Moysés RMA, Elias RM.
Int Urol Nephrol. 2022 Sep;54(9):2255-2261. doi: 10.1007/s11255-022-03116-5. Epub 2022 Jan 31.
Hyperuricemia and gout.
Lioté F.
Curr Rheumatol Rep. 2003 Jun;5(3):227-34. doi: 10.1007/s11926-003-0072-y.
Thiazide and loop diuretics.
Sica DA, Carter B, Cushman W, Hamm L.
J Clin Hypertens (Greenwich). 2011 Sep;13(9):639-43. doi: 10.1111/j.1751-7176.2011.00512.x. Epub 2011 Jul 27.
[Pathophysiology and treatment of secondary hyperuricemia].
Tsutani H.
Nihon Rinsho. 2008 Apr;66(4):699-704.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators.
Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.
Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors: A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT).
Yokose C, McCormick N, Rai SK, Lu N, Curhan G, Schwarzfuchs D, Shai I, Choi HK.
Diabetes Care. 2020 Nov;43(11):2812-2820. doi: 10.2337/dc20-1002. Epub 2020 Sep 2.
[Physiopathological aspects of secondary hyperuricemia].
Caimi G, Lo Presti R.
Recenti Prog Med. 1991 Nov;82(11):618-28.
[Secondary hyperuricemia].
Nishizawa T.
Ryumachi. 1985 Sep;25(4):313-26.
